Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)
- Sponsor
- University of Cologne
- Study ID
- NCT00346684
- Phase
- PHASE2
- Status
- Completed
Conditions
- Lymphocyte Predominant Hodgkin´s Lymphoma (LPHD)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Rituximab — DRUG
Study Details
First line therapy for patients with Lymphocyte predominant Hodgkin´s Disease (LPHD) in clinical stage IA using the monoclonal anti-CD20 antibody rituximab
Key Dates
- Start date
- Jul 31, 2006
- Status verified
- Aug 2008
- Primary completion
- Nov 30, 2007
Study Design
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT